Abraxis BioScience

Bristol Myers Squibb
Manufacturing

BMS unit in hot water with FDA over Abraxane production flubs

In an Oct. 31 warning letter addressed to BMS helmsman Giovanni Caforio, the FDA dinged Abraxis Bioscience for a raft of production issues tied to the companies’ billion-dollar cancer med Abraxane.
Fraiser Kansteiner Nov 9, 2022 12:02pm